Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN

BACKGROUND: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. METHODS: In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. RESULTS: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. CONCLUSIONS: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2026-11-13
DOI
https://doi.org/10.1681/asn.0000001296
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN

Gema Ariceta, Johan Szamosi, Andrew S. Bomback, Daniel Zecher et al.
10 links
Journal of the American Society of Nephrology
Renal Diseases and Glomerulopathies
article

Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN

Gema Ariceta, Johan Szamosi, Andrew S. Bomback, Daniel Zecher, Nabil Ziad Melhem, Giuseppe Remuzzi, Seung Hyeok Han, Larry A. Greenbaum, Masashi Mizuno, Carla Nester, Antonio Mastrangelo, Nicole C. A. J. van de Kar, Moglie Le Quintrec, Bradley P. Dixon, Eliyahu V. Khankin, Yael Borovitz, Yahsou Delmas, Marina Vivarelli, Daniel Philip Gale, Dean Wallace, Nicole M. Isbel, Zhongshen Wang, Christoph P. B. Licht, Maria Izabel de Holanda, Matthew Caleb Pickering, Fádi Fakhouri, Elena Surova, Patrick D. Walker
article en

Abstract

BACKGROUND: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. METHODS: In VALIANT's 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan (n=63) or placebo (n=61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. RESULTS: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, -67.1% [-74.9 to -56.8]; week 52, -67.2% [-75.8 to -55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (-9.6 to 17.9) (26 weeks of placebo), and -53.9% (-64.5 to -40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were -1.2 mL/min/1.73 m2 (-5.6 to 3.2) (week 26) and -3.7 mL/min/1.73 m2 (-8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were -7.9 (-11.7 to -4.2) (week 26) and -4.7 (-9.1 to -0.3) (week 52); week-26-to-52 change was +3.0 (-1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan (n=118) showed proteinuria reduction (geometric mean [95% CI] -63.0% [-69.9 to -54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [-3.8 to 4.0] mL/min/1.73 m2). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. CONCLUSIONS: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.

Journal of the American Society of Nephrology
University of Iowa (US), Biogen (United States) (US), Emory University (US), The University of Queensland (AU), University of Toronto (CA), Yonsei University (KR), Mario Negri Institute for Pharmacological Research (IT), Guy's and St Thomas' NHS Foundation Trust (GB), Columbia University Irving Medical Center (US), Hospital for Sick Children (CA), Princess Alexandra Hospital (AU), Centre Hospitalier Universitaire Vaudois (CH), Radboud University Medical Center (NL), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Centre Hospitalier Universitaire de Bordeaux (FR), University Hospital Regensburg (DE), Arkana Laboratories (US), Centre Hospitalier Universitaire de Montpellier (FR), University of Iowa Stead Family Children’s Hospital (US), Schneider Children's Medical Center (IL), Amalia Kinderziekenhuis (NL), Bambino Gesù Children's Hospital (IT), Hospital Geral de Bonsucesso (BR), Vall d'Hebron Hospital Universitari (ES), Hôpital Lapeyronie (FR), Swedish Orphan Biovitrum (Sweden) (SE), Evelina London Children's Healthcare (GB), Royal Manchester Children's Hospital (GB), University College London (GB), Imperial College London (GB), University of Colorado Anschutz Medical Campus (US), Nagoya University (JP), University of Lausanne (CH)
Good health and well-being
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon